Open an account

Arvinas

ARVN · NASDAQ

$7.66+$0.40 (+5.51%)TodayMarket closed ·
Prev close $7.26

About ARVN

Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company is headquartered in New Haven, Connecticut and currently employs 246 full-time employees. The company went IPO on 2018-09-27. The Company, through its PROteolysis Targeting Chimera (PROTAC) protein degrader platform, is pioneering the development of protein degradation therapies designed to harness the body's natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. The company is progressing multiple investigational drugs through clinical development programs, including vepdegestrant, ARV-393, ARV-102, ARV-80, and ARV-027. Vepdegestrant is an investigational orally bioavailable PROTAC protein degrader designed to target and degrade the ER for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. The company is co-developing vepdegestrant with Pfizer. ARV-393 is an investigational, orally bioavailable PROTAC to degrade BCL6, a transcriptional repressor and a regulator of normal B-cell maturation and differentiation processes. ARV-102 is in development to treat neurodegenerative diseases.

Employees
246
Headquarters
New Haven, Connecticut
Listed
Sep 27, 2018
Sector
Health Care
Industry
Pharmaceuticals
Website
arvinas.com

ARVN key statistics

Market cap
500.86M
Price-earnings ratio
30.25
Dividend yield
—
Average volume
736.73K
Volume
540.77K
Open price
$7.28
High today
$7.74
Low today
$7.28
52 Week high
$14.51
52 Week low
$6.74

Arvinas (ARVN) at a glance

Arvinas (ARVN) last traded at $7.66, with a market cap of 500.86M and a price-to-earnings ratio of 30.25.

Today the stock has traded between $7.28 and $7.74. The current price is 5.2% above the day's low and 1.0% below its high.

Volume so far is 540.77K shares, below the average of 736.73K shares a day.

Over the past year Arvinas has ranged from $6.74 to $14.51, and now sits 12% of the way up that range.

Arvinas met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q2 FY26 it reported $2.58 per share against an estimate of -$0.3772.

The average analyst price target is $14.21, 85.5% above the current price, from 8 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

75%of 8 analyst ratings say Buy
  • Buy75.0%
  • Hold25.0%
  • Sell0.0%
Price target · 16 analystsAvg $14.21
Low
$6.06
Now
$7.66
High
$22.05

ARVN earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 162.1% on average.

  1. Q3 FY24: reported -$0.68 per share against an estimate of -$0.9807
  2. Q4 FY24: reported -$0.63 per share against an estimate of -$1.04
  3. Q1 FY25: reported $1.14 per share against an estimate of -$0.9654
  4. Q2 FY25: reported -$0.84 per share against an estimate of -$1.02
  5. Q3 FY25: reported -$0.48 per share against an estimate of -$0.8098
  6. Q4 FY25: reported -$1.10 per share against an estimate of -$0.6022
  7. Q1 FY26: reported -$0.90 per share against an estimate of -$0.9375
  8. Q2 FY26: reported $2.58 per share against an estimate of -$0.3772

ARVN news

  • Full Transcript: Arvinas Q1 2026 Earnings Call

  • Vandana Singh

    Rigel Pharmaceuticals Inks Breast Cancer Drug Deal With Arvinas, Pfizer

  • Vandana Singh

    Pfizer, Arvinas Win FDA Nod For First-Of-Its-Kind Breast Cancer Therapy

  • 5 Analysts Assess Arvinas: What You Need To Know

  • Arvinas's Earnings Outlook

  • Press releasePRNewswire

    PROTAC Market Shows Accelerated Growth During the Forecast Period (2025-2034) Amid Rising Targeted Therapy Demand | DelveInsight

  • Press releaseBusiness Wire

    Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026

  • The Analyst Verdict: Arvinas In The Eyes Of 7 Experts

Similar companies

Companies in the same industry as Arvinas

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.